Today: 2 July 2026
Browse Category

Mergers & Acquisitions 25 October 2025 - 4 November 2025

Denny’s Stock Soars on Buyout Bombshell – $620 M Deal, Q3 Misses & What’s Next

Denny’s Stock Soars on Buyout Bombshell – $620 M Deal, Q3 Misses & What’s Next

Denny’s stock was under pressure for most of 2025 before the buyout news. The share price started the year in the mid-single digits and drifted lower amid uninspiring financial results and sector-wide challenges. In fact, DENN hit a 52-week low of $2.85 earlier in the yearmarketbeat.com, reflecting investors’ pessimism about growth prospects. By late October, the stock was trading around the $4 mark, not far from where it stood five years ago, and well off the 52-week high of $7.73marketbeat.com reached in late 2024. In the week heading into earnings, DENN even dipped below $4, as sentiment was subdued. The tide turned abruptly on November 3–4, 2025. Following the surprise buyout announcement after market close on Nov. 3, Denny’s stock skyrocketed in after-hours trading – up about 46.5% to ~$6.03 per sharefinviz.com. The next day the stock opened around $6, close to the deal price, and traded on heavy volume as arbitrage investors jumped in. This one-day surge single-handedly flipped Denny’s weekly performance from deep red to bright green, delivering its best day ever as a public company.
4 November 2025
···
Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Kenvue’s stock soared on the buyout news, delivering a sharp one-day gain. As of midday Nov. 3, KVUE traded around $17–$18, up roughly 18–20% intraday Reuters. Prior to the announcement, the stock had closed at $14.37 on Oct. 31 Stockanalysis, near its 52-week low of ~$14.02 Reuters Reuters. The takeover premium immediately boosted KVUE, though the share price remained a bit below the offer value – typical in cash/stock mergers as arbitragers factor in execution timing and Kimberly-Clark’s own stock movement Reuters. Overall, the market reaction reflected optimism for Kenvue shareholders locking in a significant premium after a prolonged slump. By contrast, Kimberly-Clark’s stock declined on fears of deal dilution and debt load, since KMB will partly fund the cash portion via new debt and a business unit sale Prnewswire. Today’s headline news is that Kimberly-Clark – maker of Huggies and Kleenex – announced an agreement to buy Kenvue Inc. for $48.7 billion Reuters. The deal is a mix of cash and stock, valuing KVUE at about $21.01 per share Prnewswire. Specifically, Kenvue investors will get $3.50 in cash plus 0.14625 shares of KMB for each KVUE share Prnewswire. That implies ~$40.3 B equity value for Kenvue Reuters. The takeover
3 November 2025
····
Merger Showdown: Union Slams Crédit Agricole–Banco BPM Deal Over Job Cuts and “Deserted” Towns

Merger Showdown: Union Slams Crédit Agricole–Banco BPM Deal Over Job Cuts and “Deserted” Towns

Italian bank workers’ union First CISL has delivered a stark warning about the rumored merger between Banco BPM and Crédit Agricole Italia. On October 31, the union publicly rejected the potential deal, saying it would come at a high social cost. “An eventual Crédit Agricole–Banco BPM operation will bring a new wave of branch closures [and] heavy cuts to jobs,” cautioned First CISL Secretary General Riccardo Colombanifirstcisl.it. He stressed that hundreds of bank branches could shut if the two lenders combine, hurting not only bank employees but also local communities and small businesses that rely on nearby banking servicesfirstcisl.it. The union considers this scenario “a prospect we oppose with determination.”ansa.it Colombani pointed to a pattern of consolidation-driven layoffs and branch shutdowns – a phenomenon he termed “desertificazione bancaria”. “The data on major cities prove that bank desertification is not just a problem of remote areas,” he noted, indicating that even urban centers are losing bank branchesfirstcisl.it. First CISL’s new report reveals that 268 bank branches closed in Italy from January to September 2025, and many more closures are already planned by big banks in the final quarteransa.itansa.it. This year’s retrenchment follows a longer trend of banks trimming their physical networks
3 November 2025
··
Brighthouse Financial (BHF) Stock Soars on Takeover Buzz – Price Jump, Earnings Outlook & Expert Analysis

Brighthouse Financial (BHF) Stock Soars on Takeover Buzz – Price Jump, Earnings Outlook & Expert Analysis

Deal or No Deal: In the short term, Brighthouse’s fate may hinge on the takeover negotiations. If Aquarian finalizes a buyout near $70/share, the stock could quickly gravitate toward that price and shareholders would lock in a substantial one-time gaininvesting.com. Market watchers note that private equity interest in life insurers is driven by the opportunity to earn higher returns on insurers’ investment portfoliosreuters.com. Aquarian’s rumored ~$4 billion offer underscores that strategic buyers see more value in Brighthouse than the public market does – a sentiment echoed by activists and some analysts. However, there’s no guarantee a deal is consummated: talks could still fall through or drag on if financing hurdles arisereuters.com. If no deal emerges, what’s next for Brighthouse? The stock would likely give back some of its takeover premium – it was trading in the mid-$40s before the latest headlines. But longer-term, Brighthouse could continue as an independent turnaround story. The company has been exploring “strategic alternatives” for much of 2025investing.com, so other bidders or a breakup of the company remain possible outcomes if the Aquarian route fails. Greenlight’s involvement means management is under pressure to boost shareholder value one way or another. In absence of M&A, that means
31 October 2025
···
Chevron (CVX) Stock Rallies on $2B Pipeline Deal – Could $200 Be Next?

Chevron’s Next Big Move: CVX Stock Could Skyrocket on $55B Hess Deal & Low-Carbon Push

In summary, as of Oct 31, 2025 Chevron stands as a dividend-rich, integrated energy leader navigating a weak-oil cycle. Its stock is trading near multi-month lows but backed by record production and cash flow. Short-term catalysts include the Hess synergies and any rebound in oil prices. Longer-term, Chevron emphasizes high-return oil projects and steady shareholder returns, while gradually investing in lower-carbon ventures. Key factors to watch are global oil demand trends, OPEC supply decisions, and the results of Q4 earnings. Analyst consensus sees moderate upside if oil stabilizes, but Chevron – “one of the safest bets in oil,” as one strategist put itts2.tech – will still move with the commodity. For income investors, Chevron’s high yield and solid balance sheet offer a buffer, whereas others focus on whether it can sustain growth under pressure. Sources: Company filings and Reutersreuters.comreuters.comreuters.comreuters.com; analyst reports and TS2.tech analysists2.techts2.techreuters.comreuters.com.
31 October 2025
·····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk’s $9B Shock Bid Snatches US Weight-Loss Biotech from Pfizer – Stocks React Big

Novo’s takeover push marks a sudden escalation in the weight-loss drug wars. The Danish company – maker of Wegovy and Ozempic – broke ranks on Oct. 30 by notifying Metsera’s board of its superior bidreuters.com. This move comes just days after the foundation coup at Novoreuters.com, signaling a full-aggression strategy. Metsera confirmed the offer is “superior” to Pfizer’s, giving Pfizer four business days to respondts2.tech. Pfizer CEO Albert Bourla has publicly talked up this obesity play, so Pfizer is not likely to concede easily. Unsurprisingly, Pfizer immediately denounced Novo’s counterbid as “reckless” and vowed to defend the original agreementreuters.com. Observers note Novo carefully included the contingent CVRs and claims it adhered to the “no raid” clause in its agreement with Pfizerreuters.com, so the fight may end up in arbitration if no private settlement is reached. Metsera specializes in obesity therapeutics beyond the current GLP-1 trend. Its lead drug MET-097i is designed for once-monthly dosing – potentially boosting convenience and tolerabilityreuters.com. A Phase 2b trial of MET-097i showed up to ~14.1% weight loss, results that experts have hailed as “remarkable”reuters.comts2.tech. Its second program, MET-233i, is an oral agent mimicking the hormone amylin, a different weight-control pathwayreuters.com. None of these drugs are
31 October 2025
····
Activist Investor Shocks Wall Street: $10.9B Comerica Sale Sparks Bank M&A Boom

Activist Investor Shocks Wall Street: $10.9B Comerica Sale Sparks Bank M&A Boom

Until recently, regional banks drew little activist attention. That changed when HoldCo Asset Management loudly challenged Comerica’s board. In July 2025 HoldCo issued a report warning that Comerica and other midsize banks had underperformed due to poor management decisionsts2.techts2.tech. Within weeks, Comerica’s management began formally exploring strategic options, leading to the Fifth Third deal. HoldCo’s founders Vik Ghei and Misha Zaitzeff explained that many regional bank CEOs were overpaid and under-delivering – and they vowed to “shame” boards into actionintellectia.aits2.tech. After Comerica, HoldCo moved on: it recently threatened a proxy battle at Columbia Banking and is urging Eastern and First Interstate to either change course or sellreuters.comintellectia.ai. In short, investors see this as a new activist trend in banking. As Reuters observes, “lesser known investors like HoldCo… pushing for changes” have created a “new-found nervousness even at well-run banks”reuters.com. Law firms advising banks warn that with many institutions struggling to match peer profitability, activists have fertile ground – especially now that regulators are easing merger hurdlests2.techreuters.com. The Fifth Third–Comerica merger, announced Oct 6, 2025, is the biggest U.S. bank deal so far this year. Comerica Bank agreed to sell itself for $10.9 billion in an all-stock transactionts2.tech. This combination will
31 October 2025
···
Rocket Companies Stock Blasts Off After $14B Mega-Merger – Will RKT Keep Soaring?

Rocket Companies (RKT) Stock Soars after $14B Mortgage Mega-Merger and Earnings Beat – What’s Next?

Rocket Companies has been one of 2025’s surprise gainers in the mortgage sector. Its shares peaked in the low-$20s in early October on merger excitement, but have since pulled back into the mid-$16sts2.techstockanalysis.com. On Oct. 29 the stock slid about 7% before jumping ~5% in after-hours trading on Oct. 30 after the earnings beatstockanalysis.cominvesting.com. Even after the recent dip, RKT trades far above last year’s ~$10 lowts2.tech. For context, its 52-week range is roughly $10.06–$22.55reuters.com. Investors have noted the stock’s volatility – Reuters data show its beta is ~2.2 – meaning swings are commonts2.tech. Indeed, daily moves of several percent have become normal as the market digests news. But year-to-date, RKT is up roughly 80%ts2.tech, making it one of the market’s standout performers amid a tepid housing backdrop. Much of that gain came after Rocket announced its mid-2025 acquisitions: Redfin in July and Mr. Cooper in early Oct.
30 October 2025
··
Terex (TEX) Stock Crashes 18% on Surprise REV Group Merger News

Terex (TEX) Stock Crashes 18% on Surprise REV Group Merger News

Terex’s stock slump on Oct. 30 came amid two shocks: mixed Q3 earnings results and a transformational merger announcement. After a previous close near $56, shares briefly traded in the mid-$40s, reflecting roughly an 18% intraday fallstockanalysis.comts2.tech. Ts2.tech noted that “Terex fell ~18%” after the quarter newsts2.tech, a move echoed by institutional traders and option activity. By afternoon, volume had spiked and the stock was well below pre-earnings levels. For context, the 52-week range is $31.53–$58.66stockanalysis.com, so even after the drop, shares remain above their 2025 low but well off recent highs. Q3 Financials: The official Q3 release showed net sales of $1.4B and GAAP EPS $0.98investors.terex.com. Adjusted EPS was $1.50, roughly flat with last year’s $1.46. Operating margin was 12.1%, aided by the acquired Environmental Solutions Group business, which continues to outperform legacy divisions. Free cash flow was robust at $130Minvestors.terex.com. On the surface, these results were in line with expectations, but market participants focused on a few caveats: bookings, legacy segment weakness, and guidance. Bookings were roughly $1.0B, but book-to-bill was only 0.72. Notably, Aerials and Materials Processing revenues fell due to softer construction and rental marketsinvestors.terex.com.
30 October 2025
···
Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Metsera’s share price has been on a roller-coaster amid takeover speculation. In late September, Pfizer agreed to buy Metsera for $47.50 per share in cash plus up to $22.50 in contingent paymentssec.gov. Pfizer CEO Albert Bourla said this deal “propels Pfizer into this key therapeutic area” of obesity treatmentsec.gov. Metsera CEO Whit Bernard called the deal “an excellent outcome for our shareholders” and praised the chance to “realize the promise of improved human health at scale” under Pfizer’s wingsec.gov. On Oct. 30, Novo Nordisk dramatically entered the fray with an unsolicited offer valuing Metsera at up to $9 billion. Novo’s proposal is $56.50 per share cash at signing plus up to $21.25 in contingent value rightsprnewswire.com. The Metsera board declared Novo’s bid a “Superior Company Proposal”, triggering a four-day window for Pfizer to respondprnewswire.com. Pfizer immediately denounced the move: a Pfizer press release called Novo’s bid “reckless” and warned it could “suppress competition” in obesity drugsmarkets.ft.com.
30 October 2025
····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo Nordisk’s proposal is unsolicited, meaning Metsera’s board and shareholders will now review it against Pfizer’s agreement. Novo emphasizes that Metsera’s experimental therapies would be “complementary” to its own obesity portfolioreuters.com. According to MarketScreener, the bid is $56.50 in cash per Metsera share plus $21.25 in milestone CVRsmarketscreener.com. By contrast, Pfizer’s September deal was $4.9B upfront plus CVRs, for up to ~$7.3Bts2.techreuters.com. Novo’s offer thus values the company at roughly $6.5B upfront, sweetened to ~$9B with earnouts. Novo’s CEO Maziar “Mike” Doustdar hailed the move as proof of the company’s ambition. In recent acquisitions of non-obesity assets, he said Novo was showing a “relentless ambition to move faster, go further”ts2.tech. The Metsera bid follows a sweeping boardroom shake-up at Novo, where its largest shareholder demanded faster action in the U.S. marketreuters.com. Now Novo is doubling down, essentially offering a higher price to hijack Pfizer’s deal and expand its obesity pipeline.
30 October 2025
····
Alaska-Hawaiian Merger Takes Off: Single Operating Certificate and More

Alaska-Hawaiian Merger Takes Off: Single Operating Certificate and More

Behind the scenes, Alaska’s takeoff toward full integration will be mostly transparent to customers. Travel itineraries and loyalty points carry over automatically, and the Hawaiian brand on island‑only routes remains in place airlinegeeks.com. Flight numbers and booking codes have already switched: passengers who booked on HA numbers need do nothing – their flights are now AS flights beatofhawaii.com. Free Wi‑Fi via Starlink and an expanded network will be the tangible benefits in the cabin. As Alaska’s CEO put it, the goal is “one combined airline” in terms of systems, safety and service, without sacrificing the “warmth and grace” that loyal Hawaiian customers expect flightglobal.com beatofhawaii.com. The final “Hawaiian 866” flight will be remembered as a symbolic moment, but forward‑looking travelers will notice more nonstop destinations, seamless loyalty benefits and eventually the ability to book around‑the‑world trips using oneworld routes executivetraveller.com. With integration milestones like the SOC now achieved, analysts forecast that Alaska Air Group should begin capturing the promised merger benefits. Cost synergies are expected to kick in by year‑end prnewswire.com, supporting continued profit growth. In contrast, ongoing fuel volatility remains a headwind. Stock‑market watchers will be paying close attention to Alaska’s next earnings releases and forward guidance. Still, most
29 October 2025
···
Pepsi Bottler Goes Boozy: Varun Beverages Surges on Carlsberg Beer Deal & Q3 Profit Jump

Pepsi Bottler Goes Boozy: Varun Beverages Surges on Carlsberg Beer Deal & Q3 Profit Jump

After decades of selling PepsiCo sodas and bottled water, Varun Beverages is making a bold pivot into booze. The company’s board on Wednesday approved adding alcoholic drinks to its business scope, a strategic move to diversify beyond soft drinks. “In response to the growing popularity of Ready To Drink and [a] variety of alcoholic beverages, VBL sees an opportunity for expansion into [this] business… including beer, wine, liquor, brandy, whisky, gin, rum, [and] vodka in India & abroad,” the company said in a statementndtvprofit.com. In other words, the Pepsi bottler will now also be an alcoholic beverages company, eyeing a piece of the high-growth beer, cider and spirits market. As a first step, Varun Beverages has partnered with Danish brewing giant Carlsberg. VBL signed an exclusive distribution agreement with Carlsberg Breweries A/S to launch Carlsberg beer in select African marketseconomictimes.indiatimes.com. Under this pact, VBL’s African subsidiaries will test-market Carlsberg’s flagship lager across their territorieseconomictimes.indiatimes.com. This is a significant development – it gives Varun an immediate entry into the beer segment via a well-known global brand. The company indicated that the tie-up aligns with shifting consumer demand and provides “a key opportunity to diversify its portfolio beyond soft drinks” by adding
29 October 2025
··
Cygnet’s $1.4 B Oil Patch Power Play – Kiwetinohk Shareholders Score Big Premium in Alberta Energy Deal

Cygnet’s $1.4 B Oil Patch Power Play – Kiwetinohk Shareholders Score Big Premium in Alberta Energy Deal

In a significant shake-up for the Canadian oil and gas sector, Cygnet Energy – a privately held exploration and production company – has agreed to buy publicly traded Kiwetinohk Energy Corp. in an all-cash acquisition. Announced on October 28, 2025, the definitive arrangement agreement will see Cygnet pay C$24.75 per share for all Kiwetinohk common sharesreuters.comreuters.com. This values the transaction at approximately C$1.4 billion, just shy of US$1 billion. The takeover will be executed via a court-approved Plan of Arrangement under Canadian law and is expected to close by late December 2025, assuming regulatory and shareholder approvals are obtainedreuters.com. Kiwetinohk’s board of directors has unanimously endorsed the offer as fair and in the best interest of shareholders, after a months-long sale process. “After reviewing all of our available options… the Board has determined that the arrangement is the best alternative in the current market,” said Pat Carlson, Kiwetinohk’s CEO, calling the deal a “successful conclusion” of the company’s strategic review aimed at maximizing shareholder valueboereport.comboereport.com. A special shareholder meeting is scheduled for mid-December to vote on the deal, where two-thirds support is required. Given that nearly 80% of shares are already pledged in favorboereport.com, the outcome is essentially secured barring
28 October 2025
···
Huntington Bancshares’ Bold Moves: Strong Earnings and a $7.4B Bank Takeover Shake Up HBAN Stock

Huntington Bancshares’ Bold Moves: Strong Earnings and a $7.4B Bank Takeover Shake Up HBAN Stock

October 27, 2025: Huntington Bancshares Incorporated is making headlines with a potent mix of robust earnings and aggressive expansion. The Columbus, Ohio-based regional bank is riding high on better-than-expected Q3 results and announcing a $7.4 billion takeover of Cadence Bank, a bold merger that extends Huntington’s footprint into the lucrative Texas and Southeast markets. Investors are parsing what these developments mean for HBAN’s stock price and future. As of October 27, Huntington’s stock is hovering near $15.5 per share in afternoon trading. That price is down a few percent from Friday’s close, reflecting a knee-jerk selloff after the Cadence Bank acquisition announcement reuters.com. In pre-market trading Monday, HBAN slid about 3–4%, even as Cadence’s stock popped roughly 2% on the news reuters.com. The dip suggests some investors are wary of the deal’s short-term impacts ts2.tech.
27 October 2025
··
American Water & Essential Utilities to Merge in $63B ‘Mega-Deal’ – What Investors Need to Know

American Water & Essential Utilities to Merge in $63B ‘Mega-Deal’ – What Investors Need to Know

In-Depth Report: On Oct. 26, 2025, American Water Works Co. and Essential Utilities, Inc. surprised the utilities sector by announcing a definitive all-stock merger agreement Businesswire Investing. The companies said the combination creates the largest regulated water/wastewater utility in the U.S., serving roughly 14 million people in 14 states ts2.tech. According to the companies, shareholders of each firm unanimously approved the deal, which carries a pro forma market value of about $40 billion Marketscreener Nasdaq. American Water shareholders will receive 0.305 shares for each Essential share, equating to a ~10% premium to WTRG’s recent trading range Marketscreener. Post-merger, AWK investors own ~69% of the combined company and Essential investors ~31% Marketscreener.
27 October 2025
···
Huntington’s $7.4B Texas-Tupelo Power Move: Cadence Bank Takeover Shakes Up Banking

Huntington’s $7.4B Texas-Tupelo Power Move: Cadence Bank Takeover Shakes Up Banking

On Oct. 27, Huntington Bancshares announced it will absorb Cadence Bank in a stock-for-stock merger finimize.com sec.gov. Cadence is a $53 billion-asset regional bank based in Houston/Tupelo, with 390 branches in eight states sec.gov bankingdive.com. Under the deal Huntington will issue 2.475 of its shares per Cadence share. Based on HBAN’s Oct. 24 close of $16.07, the exchange price equals $39.77 per Cadence share finimize.com bankingdive.com. This values Cadence at $7.4 billion in total finimize.com bankingdive.com. The combined bank will have about $276 billion in assets, $220 billion in deposits, and $184 billion in loans and leases reuters.com bankingdive.com. It will rank roughly top-10 in the U.S. by deposits. Notably, Huntington immediately becomes a major player in Texas – #5 in Dallas and Houston deposits, and among the top-ten across Texas and the South sec.gov bankingdive.com. The deal also gives Huntington leading position in Mississippi and strong footholds in Alabama and Arkansas sec.gov bankingdive.com. Huntington already closed its Veritex acquisition on Oct. 20, so this is a second Texas expansion in weeks sec.gov bankingdive.com.
27 October 2025
··
RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Prior to the buyout news, RNA stock had been on a steady uptrend in 2025. The share price more than doubled from the low-$20s a year ago to the high-$40s this month ts2.tech. In the past three months alone, RNA jumped ~40%, fueled by upbeat clinical updates and M&A speculation ts2.tech. The stock hit a 52-week peak of $56 in early October ts2.tech after its lead DMD therapy showed strong results and secured FDA Breakthrough designation. Shares pulled back slightly to around $49 by late October, but remained up 100%+ year-over-year ts2.tech. A major catalyst was the Novartis takeover rumor that broke on August 6, 2025: A Financial Times report revealed Novartis was eyeing Avidity, sending RNA stock up 23% to ~$47 in a single day reuters.com. That spike marked a turning point – investors began pricing in a potential acquisition premium. In the weeks after, Avidity’s stock oscillated in the upper-$40s as markets awaited either confirmation of a deal or further trial data. By the week of Oct. 23, shares were holding around $49 with relatively low volatility, reflecting the market’s “wait-and-see” stance.
27 October 2025
·····
Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Bottom Line: Avidity Biosciences’ stock is set to explode higher on Novartis’s $12 billion buyout, capping off a dramatic run fueled by breakthrough science and takeover buzz. The high-premium deal underscores the massive value of RNA therapeutics for rare diseases – and signals that big pharma’s biotech spending spree isn’t slowing down. While Avidity’s chapter as an independent company is closing, its novel treatments may reach patients faster under Novartis’s umbrella. Investors now await the finalization of the deal, as Wall Street cheers another biotech success story in the making. 🏥💥 Sources: reuters.comreuters.combusiness-standard.combiospace.combiospace.commarketbeat.comts2.techmarketbeat.comsahmcapital.comsahmcapital.combiospace.combiospace.combusiness-standard.comreuters.combusiness-standard.comreuters.comreuters.comts2.techts2.techbiospace.combiospace.combiospace.combiospace.com
26 October 2025
····
DraftKings Bets Big: Railbird Acquisition and NBC Deal Ignite Investor Frenzy

DraftKings Bets Big: Railbird Acquisition and NBC Deal Ignite Investor Frenzy

In early August, DraftKings reported blowout Q2 results – revenue of $1.51 billion and adjusted EBITDA of $301 million, more than double the prior recordinvesting.com. Management noted strong sportsbook hold and growth in monthly active users. CEO Jason Robins said, “We set records for revenue, net income and Adjusted EBITDA in the second quarter”investing.com. The company reaffirmed its full-year outlook, expecting to hit the high end of $6.2–6.4B revenue and roughly $850M EBITDAinvesting.com. The upbeat results lifted DraftKings shares and helped narrow the gap with archrival FanDuel. Investor sentiment has bounced between excitement and caution. The summer rally gave way to a late-September swoon: DKNG’s stock tumbled over 20% as fears grew about new competitors. Many analysts trimmed price targets – for example, Susquehanna’s Joe Stauff noted the industry is entering a “more mature and competitive phase” where profitability matters more than raw growthdeadspin.com. But the early October Berenberg upgrade argued that fears were overblown. Berenberg analysts wrote that they saw “no fundamental change in demand” or “impact on numbers so far” from prediction-market entrantsmarkets.financialcontent.com, and they maintained a strong revenue/EBITDA forecast. DraftKings’ stock rallied on that news.
25 October 2025
·
1 … 15 16 17 18 19 20

Stock Market Today

  • Figma (NYSE:FIG) pops 11.8% after landing in Russell 3000, options trading jumps
    July 2, 2026, 4:16 PM EDT. Figma (NYSE:FIG) soared 11.8% to $21.79 after news of its addition to the Russell 3000 index sent buyers in. The index is tied to $12.2 trillion in assets. That move set off a wave of call buying and short covering, helping push shares up even as tech stocks sold off. Options activity was busy, with a low put/call ratio showing strong bullish flow. Still, FIG is down 34% from a year ago and sits 85% off its 52-week high. Dealers scrambled to hedge big call positions, and traders said the spike was driven by demand linked to index inclusion. Some are still watching for proof of AI-fueled sales growth from Figma to support the gains. U.S. markets closed early for Independence Day, and eye more volatility with Russell's rebalancing Friday.
Go toTop